The USPSTF issued a new draft recommendation for cervical cancer screening, recommending screening with cervical cytology every 3 years for women aged 21 to 29, and offering a choice between cytology every 3 years and high-risk human papillomavirus testing every 5 years for those aged 30 to 65 years.
A large database study found that most patients with stage I endometrioid epithelial ovarian cancer or ovarian clear cell cancer do not have better survival outcomes when treated with adjuvant chemotherapy.
This video reviews results of a phase III trial that compared pelvic radiation therapy vs vaginal cuff brachytherapy plus chemotherapy in patients with early-stage, high-risk endometrial cancer.
Weekly dose-dense chemotherapy can be delivered successfully and with lower toxicity than standard 3-weekly regimens, but it does not improve progression-free survival among patients with epithelial ovarian cancer, according to a large new study presented at the ESMO.
Two studies on Lynch syndrome highlight cancer screening and surveillance opportunities.
Women with increased levels of cadmium, which mimics estrogen in the body, had a higher risk of endometrial cancer, according to a recently published observational study.
Olaparib tablet maintenance therapy provided a significant improvement in progression-free survival over placebo in patients with relapsed, platinum-sensitive ovarian cancer with a BRCA1/2 mutation.
Women who undergo HPV testing following a test showing abnormal cytology have earlier detection of high-grade cervical intraepithelial neoplasia, compared to those who do not undergo HPV testing.
Niraparib is the most effective but most costly of the currently FDA-approved PARP inhibitors for the treatment of recurrent ovarian cancer.
Almost one quarter of long-term cervical cancer survivors reported experiencing chronic fatigue, according to a study conducted in Norway.